IL278575B1 - Dantrolene formulations and methods of using them - Google Patents

Dantrolene formulations and methods of using them

Info

Publication number
IL278575B1
IL278575B1 IL278575A IL27857520A IL278575B1 IL 278575 B1 IL278575 B1 IL 278575B1 IL 278575 A IL278575 A IL 278575A IL 27857520 A IL27857520 A IL 27857520A IL 278575 B1 IL278575 B1 IL 278575B1
Authority
IL
Israel
Prior art keywords
methods
dantrolene formulations
dantrolene
formulations
Prior art date
Application number
IL278575A
Other languages
English (en)
Hebrew (he)
Other versions
IL278575A (https=
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of IL278575A publication Critical patent/IL278575A/en
Publication of IL278575B1 publication Critical patent/IL278575B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL278575A 2018-05-21 2020-11-09 Dantrolene formulations and methods of using them IL278575B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674394P 2018-05-21 2018-05-21
PCT/US2019/033260 WO2019226621A1 (en) 2018-05-21 2019-05-21 Dantrolene formulations and methods of their use

Publications (2)

Publication Number Publication Date
IL278575A IL278575A (https=) 2021-01-31
IL278575B1 true IL278575B1 (en) 2026-03-01

Family

ID=66821419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278575A IL278575B1 (en) 2018-05-21 2020-11-09 Dantrolene formulations and methods of using them

Country Status (15)

Country Link
US (1) US20210236467A1 (https=)
EP (1) EP3796889A1 (https=)
JP (2) JP7762489B2 (https=)
KR (1) KR20210011961A (https=)
CN (1) CN112135605A (https=)
AU (1) AU2019272577B2 (https=)
BR (1) BR112020023012A2 (https=)
CA (1) CA3101093A1 (https=)
IL (1) IL278575B1 (https=)
MA (1) MA52707A (https=)
MX (2) MX2020012464A (https=)
SG (1) SG11202011121UA (https=)
UA (1) UA127661C2 (https=)
WO (1) WO2019226621A1 (https=)
ZA (1) ZA202006986B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419795A (zh) * 2020-05-09 2020-07-17 上药东英（江苏）药业有限公司 一种注射用丹曲林钠混悬剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene
US20170143677A1 (en) * 2001-06-23 2017-05-25 Lyotropic Therapeutics, Inc. Treatment using dantrolene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1361092A (en) 1992-03-10 1993-10-05 Kyukyu Pharmaceutical Co., Ltd. Pharmaceutical preparation for percutaneous administration
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143677A1 (en) * 2001-06-23 2017-05-25 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2010126818A1 (en) * 2009-04-27 2010-11-04 Usworldmeds Llc Intranasal delivery system for dantrolene

Also Published As

Publication number Publication date
AU2019272577B2 (en) 2024-08-08
MA52707A (fr) 2021-03-31
JP2021524855A (ja) 2021-09-16
CN112135605A (zh) 2020-12-25
ZA202006986B (en) 2024-04-24
MX2025002392A (es) 2025-04-02
IL278575A (https=) 2021-01-31
UA127661C2 (uk) 2023-11-22
JP2024023270A (ja) 2024-02-21
CA3101093A1 (en) 2019-11-28
SG11202011121UA (en) 2020-12-30
AU2019272577A1 (en) 2020-11-26
BR112020023012A2 (pt) 2021-02-02
KR20210011961A (ko) 2021-02-02
JP7762489B2 (ja) 2025-10-30
MX2020012464A (es) 2021-02-09
EP3796889A1 (en) 2021-03-31
WO2019226621A1 (en) 2019-11-28
US20210236467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
IL274276A (en) CASZ preparations and methods of use
IL276687A (en) Trialkyne coupling agents and methods of using them
GB2582100B (en) CAS12C Compositions and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL276135A (en) Preparations and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL274045B1 (en) Prodrugs of dantrolene and methods of using them
IL285928A (en) Fulvestrant formulations and methods of using them
GB202105087D0 (en) Microbial compositions and methods of use
SG11202009315WA (en) Formulation and method of preparation
ZA202207188B (en) Liquid tasimelteon formulations and methods of use thereof
IL276053A (en) Therapeutic Gard and methods of its use
ZA202000502B (en) Cosmetic compositions and methods of use
IL280000A (en) Formulations for reducing tumors and methods of using them
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
GB2589398B (en) Compounds and methods of use
IL274433A (en) Fulvestrant formulations and methods of using them
IL278575B1 (en) Dantrolene formulations and methods of using them
GB201610176D0 (en) Imaging agents and methods of use
GB201818904D0 (en) New formulations and methods
HK40047046A (en) Dantrolene formulations and methods of their use
HK40045754A (en) B7-h7-binding agents and methods of use thereof
HK40053358A (en) Anellosomes and methods of use